Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide versus placebo in adolescents with obesity and weight-related comorbidities
MOH_2024-08-19_012332Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Tirzepatide with Placebo (2 arms). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on MOH_2024-08-19_012332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-19_012332.